There are 26 records that matched your search criteria

Date Title Category
24-Mar-2016 44th PhAMA Annual General Meeting 2016
12-Nov-2009 8th List for BE Studies for Oral “Immediate Release” Generic Products
Bil (46) dlm. BPFK/PPP/01/03 dated 30th October 2009
DCA letters
15-Sep-2009 Advertisement on Products for nicotine replacement therapy with MAB Approval
Bil (37) dlm KKM-55/205/001/02 Jld 5 dated 15th Sept 2009
MAB Letter
23-Feb-2011 Briefing on 'Competition Act 2010'
by the Ms Shila Dorai Raj, Director of the Interim Competition Commission, MDTCC
General News
22-Jul-2010 Caution Statement on "Boxed warning" must include Propylthiouracil with "Severe Liver Injury"
Bil (55) dlm. BPFK/PPP/01/03 dated 22nd Jul 2010
DCA letters
13-Oct-2009 Caution Statement on “Increased Risk for Opportunistic Infections such as Activation of Latent Viral Infections Including BK Virus-Associated Nephropathy” required to be included in the product package insert for Immunosuppressant
Bil (44) dlm. BPFK/PPP/01/03 dated 13th October 2009
DCA letters
14-Sep-2009 Caution Statement on “Possible Interaction between Clopidogrel and Proton Pump Inhibitors” required to be included in the product package insert for Clopidogrel
Bil (42) dlm. BPFK/PPP/01/03 dated 14th Sept 2009
DCA letters
14-Sep-2009 Caution Statement on “Potential For an increase in risk of Hepatotoxicity” required to be included in the product package insert for Propylthiouracil
Bil (41) dlm. BPFK/PPP/01/03 dated 14th Sept 2009
DCA letters
14-Sep-2009 Caution Statement on “Potential For an increase in risk of Hepatotoxicity” required to be included in the product package insert for Propylthiouracil
Bil (41) dlm. BPFK/PPP/01/03 dated 14th Sept 2009
DCA letters
14-Sep-2009 Caution Statement on “Potential for an Increase in Risk of Suicidal Thoughts or Behaviours” required to be included in the product package insert for Antiepileptik.
Bil (43) dlm. BPFK/PPP/01/03 dated 14th Sept 2009
DCA letters
13-Oct-2009 Caution Statement on “Severe Drug Interaction Between Colchicine and P-Glycoprotein or Strong CYP3A4 Inhibitors” required to be included in the product package insert for Colchicine
Bil (44) dlm. BPFK/PPP/01/03 dated 13th October 2009
DCA letters
16-Aug-2010 Cosmetic products that are use around the eye and packaging that are not permitted for the product.
Bil (40) dlm. BPFK/17/K/2.2 dated 16th Aug 2010
DCA letters
15-Mar-2016 Introduction and List of PhAMA Training Premises for Provisionally Registered Pharmacist (PRP)
General News
14-Jun-2011 Joint MyIPO-PhAMA Seminar on '1 Malaysia Medicines: The Way Forward in Intellectual Property'
MyIPO Office, Level 12A, Menara UOA, Jalan Bangsar Utama 1, Bangsar, Kuala Lumpur
14-Jun-2011 MyIPO-PhAMA IP Seminar on Intellectual Property: 'The Way Forward' - Post event Videos and Photos
The MyIPO-PhAMA IP Seminar on Intellectual Property: "The Way Forward", was held on Tuesday 14 June 2011 at the...
04-Mar-2015 News Coverage on GST Media Roundtable
General News
25-May-2010 NPCB Circular on Quest 3 launch
Bil (49) dlm. BPFK/PPO/03/02 dated 25th May 2010
NPCB
23-Feb-2011 PhAMA 39th AGM Notice - 31 March 2011
General News
23-Feb-2011 PhAMA Annual Games 2011
General News
12-May-2010 PhAMA participated in the NKEA Workshop organized by PEMANDU.
On 12 May 2010 at the Malaysia Airlines Academy, PhAMA participated in the National Key Economic Areas (NKEA)...
General News